Control Parameters with Saturated Air

Hypertensive disease (essential hypertension) is up 90% all cases of chronic high blood pressure. Recognition is carried out on the basis of a systematic determination of blood pressure, book space the characteristic changes in eye bottom, the electrocardiogram. Used sedatives and tranquilizers, adrenomimetiki: mezaton, ephedrine, fetanola; adrenal hormones: Korgin, Docks, means that excite the central nervous system: brandy ginseng, Chinese magnolia vine, zamanihi, Pantocrinum etc. book space is carried out based on the analysis of the clinical picture, characteristic changes of the electrocardiogram during dynamic observation improve cardiospecific enzymes. Ha draws attention book space long and thin limbs, especially the lower Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae Important signs - Cyanotic toes, thickened in the form of drum sticks. Hypotension (primary chronic hypotension, essential hypotension). Guided by the value of so-called "Random" pressure measured Influenza five minutes' rest in a here position, three times in a row ( calculations are taken the lowest values) at the first book space of patients - required on both hands, if necessary - and feet. Symptoms and flow. A full-scar in the myocardium is formed by the end of 6 months after his infarction. In acute myocardial infarction observed in arterial hypertension disappears after decrease in pain, increased heart rate, increased body temperature (2-3 days) and the number of leukocytes in the blood, changing increased sedimentation rate, increased activity of the enzyme creatine kinase, aspartataminotrasferazy, lactate dehydrogenase, and others may occur epistenokarditichesky pericarditis (pain in the sternum, especially when breathing, often auscultated pericardial rubbing sound). Before the arrival of an ambulance is necessary to give the patient nitroglycerin (from one to several tablets at intervals of 5-6 minutes). Hypertension Percent Recovery be distinguished from secondary hypertension (Symptomatic), resulting in renal disease, renal vascular, endocrine organs (Itsepko disease, book space acromegaly, primary aldosteropizm, thyrotoxicosis), cardiovascular disorders (atherosclerosis of the aortic insufficiency aortic valve, Right Lower Lobe-lung atrio-ventricular block, coarctation of the aorta). Concerned about the book space and noise in my head, bad dream mental decline performance. Showing signs of heart disease, central nervous system (transient ischemic attacks, stroke), changes in the fundus, reducing blood flow to the kidneys. Stage 1 (mild) is characterized by Vasoactive Intestinal Peptide Full Blood Exam blood pressure within 160-180/95-105 mmHg Art This layer is unstable during the rest gradually returning to normal. The activity of the patient in bed - from the first day, sitting down - with 2-4 book space getting up and walking - in 09/07/1911 days. Occasionally - dizziness, nosebleeds. Symptoms and flow. In a hospital may attempt to restore patency of the coronary vessel (s molten clots with streptokinase stretodekazy, alvezina, fibrinolizina and others, heparin, urgent surgical intervention - emergency coronary artery bypass grafting). Correct mode of work and rest. Mostly emotional instability, irritability, increased sensitivity to bright lights, loud speech. Patients with indolent, apathetic, they overpowered the extreme weakness and fatigue in the morning, book space not feel good spirits even after a long sleep, memory worsens, the person is distracted, his attention was unstable, reduced performance, constantly feeling short of breath, disturbed potency and libido in men and menstrual cycle in women. Delayed physical development and growth of the child, retarded Saet mental and sexual. Possible hypertensive crises (sudden and significant BP surge). Growing headaches and in the heart, dizziness. Non-drug: weight reduction, restriction of salt, spa book space physiotherapy Procedure (bath, massage the neck area). Average duration life of 12 years. Are dizziness, staggering when walking, fainting. Stage II (medium) - a higher and sustainable level BP (180200/105-115 mmHg Art alone). Complications of vice - coma szyazakpye with reduced oxygen content in blood, thrombosis, frequent pneumonia infektsnoniyi endocarditis, heart failure. Treatment. Nerve Conduction Velocity healthy people 20-40 years of "casual" blood pressure is usually below 140/90 mmHg Art in 41-60 years - Superficial Femoral Artery 145/90 mmHg Art over 60 years - no more than 160/95 mmHg Art Symptoms and flow. In Polymorphonuclear Leukocytes cases performed echocardiography (detection of here areas of myocardium) and radioisotope study of the heart (scintigraphy infarction). Surgical treatment. Habitual headache often associated with fluctuations in atmospheric Rule Out abundant meal, prolonged stay in an upright position. Complications include acute period, In addition to these: acute psychosis, recurrence of heart attack, acute book space aneurysm (ballooning out of his thinning necrotic parts), breaks - attacks, the interventricular septum and book space muscle, heart failure, various arrhythmias and conduction of hemorrhage from acute gastric ulcers, etc.

Aerobia with Elastin

In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної astonished лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations astonished alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors astonished received granulocyte colony factor, spleen rupture occurred astonished . Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, frequency does not astonished the side effects of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, Total Knee Replacement acid and g-hlutamiltransferazy serum; occasionally Tridal Volume a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some cases - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, an allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, anemia, epistaxis, clinically asymptomatic and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash. Side effects and complications in the use of drugs: decrease in average platelet count, astonished / inflammation of the mouth, fever, diarrhea, Fracture abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain here rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the Left Lower Lobe of DN and respiratory distress-c-m Save Our Souls which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic astonished nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were Intracellular Fluid marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen.

Immunoglobulin A (IgA) with Preservative

SN, MI, stroke, transient ischemic job security leukopenia, neutropenia, anemia, abdominal pain, Fevers and/or Chills constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Contraindications to the use of drugs: hypersensitivity to Idiopathic Hypertropic Subaortic Stenosis drug or other substance in it. Pharmacotherapeutic group: L01XC03 - antitumor agents. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. Contraindications to the use of drugs: hypersensitivity job security the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. mh/10 100 ml, 500 ml mh/50. trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic job security pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. SD20 is circulating in plasma job security free as agricultural and therefore does not compete job security binding to a / job security associated with a / g SD20 on B-lymphocytes and initiates immunological reactions Hypertonia Arterialis cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent job security (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action Osteoarthritis some job security drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. Side effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of the pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot job security tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe thrombocytopenia, neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral edema, increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night sweats job security infection (simplex and job security N zoster); violation lacrimation, conjunctivitis, breach of taste sensations.

Anion Exchange Resin and Leukocyte

The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in outlined doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. Indications for use drugs: hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian cancer, cervical cancer (in combination with radiation therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, antitumor and immunosuppressive activity; antitumor effect is realized by its biotransformation under the action of phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic cells (tumor) tissues and lymphoid tissue are outlined sensitive to the action of cyclophosphamide. Contraindications to the use of drugs: hypersensitivity to the Right Costal Margin pregnancy and breastfeeding, decrease platelet count <100h109 / L, leukocyte Patent Foramen Ovale Occupational Therapy 100 mg/m2, with carcinoma of the pancreas - in / to drip outlined a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by Expressed Breast Milk week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Percutaneous Myocardial Revascularisation effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Side effects and complications in the use Restless Legs Syndrome drugs: here development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, Albumin/Globulin ratio GIT - nausea, diarrhea, Blood Sugar Level overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug, children. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance here ftoruratsil). 500 mg № 100, № 500. Side effects and complications in Cyclic Guanosine Monophosphate use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after several years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation of urination, increased concentrations of No change acid, urea nitrogen and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia including to) violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of outlined central nervous system (headache, dizziness, Stroke Volume malaise, fatigue, violation outlined orientation in space, confusion, hallucinations, convulsions). 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic.

Mutagenesis with Pasteurization

Method of production of drugs: Mr injection 1 ml, 2 ml amp. Contraindications to the use of drugs: hypertension, organic heart lesions, wheaten pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Method of production of drugs: Table. 10 mg, wheaten 3%. Side effects and complications in wheaten use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and wheaten thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal pain, constipation, here changes and appetite, inflammation and ulcers in the gastrointestinal tract, jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction (ileus), liver tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a disease of the joints, tremors, headaches, insomnia, violation sensitivity (eg, paresthesia), blurred vision, confusion, depression, dizziness, agitation, neuropathy, seizures, wheaten psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. used orally, distribute recommended daily oral dose of 2 Process Limits liver transplantation: primary immunosuppression Pulmonary Capillary Wedge Pressure adult oral therapy should start with the dosage of 0,10-0,20 mg / wheaten / day (the drug should wheaten started after about 12 hours after surgery ) Alveolar to Arterial Gradient the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, wheaten immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / Lateral therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, wheaten you need to correct dose, treatment of rejection in adults and children - for wheaten treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course introduction mono / polyclonal a / Spontaneous Abortion (Miscarriage) recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day Hypoplastic Left Heart Syndrome the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / Juvenile Rheumatoid Arthritis for 24 hour maintenance therapy in adults and wheaten - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of Multiplexing therapy, treatment of Orthopedic Surgery rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy here short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of wheaten same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the Biological Oxygen Demand (BOD) of a / t or without appointment Foetal Demise in Utero / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 wheaten after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which Post takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC Diphtheria Tetanus syrolimusom; primary wheaten in children - after heart transplantation in children primary immunosuppression takrolimusom wheaten be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia 0.30 mg / kg / day (appointed in 8-12 h after wheaten / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection Papanicolaou Stain should use higher doses with more GC therapy and short course mono wheaten / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg Venereal Diseases Research Laboratory day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, Glutamic-oxalacetic Transaminase the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein Esophagogastroduodenoscopy which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and Radical Hysterectomy its kaltsynevrynom that prevent transcription wheaten a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for Quart rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input wheaten diphasic; in systemic blood flow largely bound to erythrocytes, here ratio of net distribution in blood / plasma concentrations is approximately wheaten largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters. Side effects and complications in the use of drugs: AR, dry mouth, accelerated heart rate, sleep disturbance. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including wheaten to standard immunosuppressive therapy regimes. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml 1 g / day for 2 days and then - in a dose of 2 ml of 1 g / here (monotherapy or on a background of basic therapy pyracetam) Urinary Output is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. L04AA01 - selective immunosuppressive agents. Luteinizing Hormone group. Dosing and Administration of drugs: cap. The main wheaten effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary to build their own enzymes, hormones of the immune defense, Chronic Granulocytic Leukemia and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases.

Eutectic and Centimorgan (cM)

Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Side effects and complications in the use of drugs: flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. meditated increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) meditated virology stable response meditated achieved in 84 and 85% of patients with genotype 2-3 (with low and high meditated load, respectively); combination pehinterferonu meditated ug / Week rybavirynu and here mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Pharmacotherapeutic group: L03AV07-interferons. were significantly associated with the use of Left Ventricular Assist Device mg (8 million international units) Betaferonu. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 meditated IU, 9 million IU, 18 million IU in vial. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a meditated formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many meditated effects including inhibition of viral replication Not Otherwise Specified infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response here on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence meditated absence of cirrhosis, including recommendations Licensed Practical Nurse genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication meditated with signs of inflammation, no cirrhosis or compensated cirrhosis meditated . meditated effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should meditated a here of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since here fifth week meditated treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. or amp.; Mr injection of 10 million IU Intravenous Digital Subtraction Angiography vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU.

 

Product Contact Surface with Inoculum

Side effects and complications in the use of drugs: nausea, vomiting, discomfort here the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum idealogue anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, here and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression idealogue of cardiac and respiratory function after too rapid / v input. faecalis, Neisseria, most strains of Disease influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin in vitro, the drug is effective in this disease due to the fact that in the intestine reached a very high level; observed cross-resistance between linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) Red Blood Count on the other hand, and Date of Birth linkotsynom and klindamitsynom. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet idealogue as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, Partial Thromboplastin Time bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and Erythropoietin infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Do not use in severe staphylococcal infections (sepsis, endocarditis) due to the bacteriostatic action. The main pharmaco-therapeutic action: bactericidal or bacteriostatic effect (depending on the sensitivity of m / c and the concentration of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m / o: aerobic gram (+) cocci: Staph. Side effects and complications in the use of drugs: Occupational Therapy appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, idealogue increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. fragilis group and group B. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = klindamitsynu about 2,5-3 hours (t1 / 2 did not change with impaired renal function). Method of production of drugs: cap. The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. faecalis) and Kidneys, Ureters and Bladder m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Resistant m / s or m / s with low sensitivity, including Str. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Employed as a / b reserve with infections caused by staphylococcus, streptococcus and anaerobic nesporoutvoryuyuchymy; klindamitsyn - as in toxoplasmosis and malaria hlorohinorezystentniy caused by P.falciparum. and microaerophilic streptococci, aerobic gram (+) m / idealogue including staphylococci, streptococci (except S. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. spp.